Sana Biotechnology, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $132.0M | $215.7M | $261.8M | $285.9M | $248.6M |
| Operating expenses | $250.3M | $272.7M | $293.1M | $272.6M | $356.9M |
| Operating income | -$250.3M | -$272.7M | -$293.1M | -$272.6M | -$356.9M |
| Pretax income | — | — | — | — | -$355.9M |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$244.2M | -$266.8M | -$283.3M | -$269.5M | -$355.9M |
| Balance Sheet | |||||
| Cash and equivalents | $71.9M | $127.6M | $133.5M | $176.8M | $253.0M |
| Current assets | $148.7M | $160.8M | $213.5M | $444.4M | $558.1M |
| Total assets | $416.9M | $501.0M | $565.3M | $822.7M | $1.1B |
| Current liabilities | $78.7M | $45.4M | $64.5M | $111.5M | $99.2M |
| Total liabilities | $256.0M | $250.5M | $277.8M | $323.4M | $400.9M |
| Stockholders' equity | $160.9M | $250.5M | $287.5M | $499.3M | $728.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$143.8M | -$223.2M | -$253.6M | -$290.1M | -$251.1M |
| Depreciation and amortization | $12.8M | $15.5M | $17.5M | $15.6M | $11.1M |
| Stock-based compensation | $25.5M | $37.7M | $35.5M | $38.3M | $22.4M |
| Capital expenditure | $938,000 | $33.4M | $20.0M | $20.9M | $29.9M |
| Free cash flow | -$144.8M | -$256.6M | -$273.6M | -$310.9M | -$280.9M |
| Impairments | $44.6M | $1.9M | $7.0M | $0 | $0 |
Shares outstanding 278.3M · Free float 68.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.